40 stories
TB-500 is a synthetic short-chain analog of thymosin β-4, an endogenous peptide involved in cell migration and angiogenesis. Like BPC-157, it has been heavily marketed for tendon, ligament, and muscle repair on the strength of preclinical and animal data, without approved human indications.
On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 to recommend adding TB-500 to the Section 503A Bulks List. The vote overrode FDA career-staff briefing documents (released June 29-30) that recommended against inclusion, citing thin human clinical trial evidence, questions about identity and purity in compounding-channel samples, and gray-market marketing patterns. The recommendation is advisory only; FDA rulemaking to actually add TB-500 to the bulks list takes approximately 6-18 months from the date the agency decides to act.
Before the PCAC vote, TB-500 sat in FDA Category 2 (insufficient information to evaluate). It appears in DOJ misbranding cases and state medical board enforcement actions alongside BPC-157. Most usage runs through unregulated peptide clinics and online research-peptide vendors. ProPublica's 2026 reporting on the FDA's 2023 effective ban listed TB-500 among the 19 injectable peptides at issue.
Stories here cover the PCAC outcome, regulatory status, enforcement cases, and any movement toward registered human trials. See #pcac, #peptide-compounding, and #thymosin-beta-4 for adjacent threads.
Combining multiple peptides like GHK-Cu, BPC-157, and TB-500 is becoming a growing trend, especially among GLP-1 medication users dealing with skin laxity from rapid weight loss. Goop feature explores risks and benefits with dermatologist input.
The regulated peptide market is worth $50 billion and projected to double by the early 2030s. Unregulated peptides like BPC-157 and TB-500 lack rigorous human safety data and are increasingly sourced from gray-market Chinese distributors.
Comprehensive look at peptide therapies from approved GLP-1s to unregulated substances like BPC-157 and TB-500. Most evidence comes from animal studies, with benefits "largely unvalidated in human trials."
A research review characterizes TB-500 and BPC-157 as distinct informational modulators, with TB-500 linked to thymosin beta-4 biology and BPC-157 acting as a localized signaling stabilizer.